Table 2. Clinical Course Over 52 Weeks.
| No. | Age (years) | Sex | Disease location | Pretreated |
Baseline |
Treated |
At 10 weeks |
At 24 weeks |
At 52 weeks |
Clinical course |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TAC LOR | PSL (mg) | Full Mayo | Endo scores | CRP (mg/dL) | ADA | Intensive GMA | Full Mayo | Endo scores | CR | CRP (mg/dL) | PSL (mg) | p Mayo | CRP (mg/dL) | Full Mayo | Endo scores | CR | CRP (mg/dL) | ADA continued | Failed/flare (weeks) | AZA (mg) | AE | ||||
| 1 | 50 | M | Left-sided | - | 5 | 8 | 3 | 0.04 | + | + | 5 | 2 | - | 0.04 | 0 | 0 | 0.02 | 1 | 1 | + | 0.02 | + | - | - | - |
| 2 | 34 | F | Left-sided | - | 5 | 6 | 2 | 0.3 | + | + | 2 | 1 | + | 0.13 | 0 | 1 | 0.06 | 2 | 1 | + | 0.06 | + | 32 | 50 | - |
| 3 | 65 | M | Extensive | + | 40 | 11 | 3 | 2.52 | + | + | 2 | 1 | + | 0.34 | 0 | 1 | 0.14 | 2 | 1 | + | 0.1 | + | - | - | - |
| 4 | 71 | F | Extensive | - | 40 | 12 | 3 | 27.9 | + | + | 12 (4 weeks) | ope | 40 (4 weeks) | - | |||||||||||
| 5 | 43 | M | Extensive | - | 60 | 12 | 3 | 0.55 | + | + | 6 | 1 | - | 0.03 | 0 | 1 | 0.03 | 1 | 0 | + | 0.03 | + | 12 | 25 | + |
| 6 | 85 | M | Extensive | - | 60 | 9 | 2 | 1.7 | + | + | 1 | 1 | + | 1.1 | 0 | 0 | 0.09 | 1 | 1 | + | 0.25 | + | - | - | + |
| 7 | 52 | M | Extensive | - | 15 | 10 | 3 | 2.03 | + | + | 1 | 1 | + | 0.08 | 0 | 0 | 0.09 | 3 | 1 | - | 0.3 | + | 56 | 50 | - |
| 8 | 35 | F | Extensive | - | 10 | 6 | 1 | 0.03 | + | + | 0 | 0 | + | 0.03 | 0 | 0 | 0.03 | 1 | 1 | + | 0.03 | + | - | - | - |
| 9 | 77 | F | Extensive | + | 15 | 10 | 3 | 1.55 | + | + | 3 | 2 | - | 0.09 | 0 | 1 | 0.03 | 2 | 1 | + | 0.03 | + | 10 | 25 | + |
| 10 | 59 | M | Extensive | - | 15 | 9 | 2 | 1.0 | + | + | 7 | 2 | - | 0.12 | 10 | 2 | 0.03 | 3 | 1 | - | 0.03 | + | 10 | 25 | - |
One patient received total colectomy at 4 weeks because of no response to combination therapy of ADA plus intensive GMA. TAC: tacrolimus; LOR: loss of response; PSL: prednisolone; CRP: C-reactive protein; ADA: adalimumab; GMA: granulocyte and monocyte adsorptive apheresis; p Mayo: partial Mayo; CR: clinical remission; failed: failure to achieve clinical remission; AZA: azathioprine; AE: adverse events.